期刊文献+

老年S状室间隔与非S状室间隔患者行化学消融的比较 被引量:1

Comparison the effectiveness and safety of PTSMA between aged sigmoid septum patients and aged neutral septum patients with hypertrophic obstructive cardiomyopathy
原文传递
导出
摘要 目的:总结60岁以上老年S状室间隔患者与老年非S状室间隔肥厚型梗阻性心肌病(HOCM)患者行心肌化学消融术(PTSMA)治疗的疗效及并发症发生情况。方法:对2009-07-2013-06实施PTSMA治疗的60岁以上老年S状室间隔患者与老年非S状室间隔HOCM患者的临床资料和化学消融结果进行比较。结果:共4例老年S状室间隔患者接受PTSMA治疗,术后比术前静息及期前收缩后左心室流出道压力阶差明显下降(11.5mmHg︰56.5mmHg,P=0.037;32.5mmHg︰121.5mmHg,P=0.037)。老年非S状室间隔HOCM患者共15例接受PTSMA治疗,术后比术前静息及期前收缩后左心室流出道压力阶差亦明显下降(11.0mmHg︰67.0mmHg,P=0.001;42.0mmHg︰123.0mmHg,P=0.000)。老年S状室间隔患者与老年非S状室间隔HOCM患者手术前后静息及期前收缩后左心室流出道压力阶差变化值无明显差异(△45.0 mmHg︰△50.0mmHg,P=0.874;△84.5mmHg︰△80.0mmHg,P=0.874)。两组总并发症发生率无明显差异(P=1.000)。所有患者出院后均随访1年,无新发死亡患者,无心力衰竭加重,无心肌梗死发生,无再次行PTSMA治疗患者。结论:老年S状室间隔患者可能同老年非S状室间隔HOCM患者一样,行PTSMA治疗均有明显疗效。 Objective:To retrospectively compare the effectiveness and complication of percutanous translumi- nal septal myocardial ablation(PTSMA) performed on hypertrophic obstructive cardiomyopathy (HOCM) patients with sigmoid or neutral septum. Method: We retrospectively analyzed the data from aged sigmoid septum patients and aged neutral septum patients with HOCM treated by PTSMA from July 2009 to Jun 2013, including clinical data, and the results and complications of PTSMA were assessed. Results:There were 4 aged sigmoid septum pa- tients received PTSMA in which left ventricular outflow tract pressure gradient (LVOTPG) at rest and post pre- mature beat dropped significantly after operation(ll. 5 mmHg vs 56.5 mmHg, P:0. 037-32.5 mmHg vs 121.5 mmHg, P=0. 037). There were 15 aged neutral septum patients with HOCM received PTSMA in which left ven- tricular outflow tract pressure gradient (LVOTPG) at rest and post premature beat dropped significantly after op- eration(ll.0mmHgvs67.0mmHg, P=0.001;42.0mmHgvs123.0mmHg, P--0.000). And the decline value at rest and post premature beat had no significant difference (Δ45.0 mmHg vs Δ50.0 mmHg, P:0. 874;Δ84. 5 vs Δ80.0 mmHg, P=0. 874)between two groups. During operation and post-operative in the hospital, the total complication rate had no significant difference(P: 1.00)between two groups. There were no death, no myocardial infarction, no heart failure and no 2nd PTSMA patients during the 1 year of follow-up. Conclusion: The PTSMA for aged sigmoid septum HOCM patients is as effective as for aged neutral septum patients with HOCM.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2015年第5期556-559,共4页 Journal of Clinical Cardiology
关键词 心肌病 肥厚性梗阻型 经皮室间隔心肌化学消融术 老年S状室间隔 hypertrophic obstructive cardiomyopathy percutaneous transluminal septal myocardial ablation the aged sigmoid septum
  • 相关文献

参考文献11

  • 1BONNE G, CARRIER L , RICHARD P, et al. Fa- milial hypertrophic cardiomyopathy: from mutations to functional defects [J]. Circ Res, 1998 , 83:580-- 593.
  • 2李占全,张明,关汝明,金元哲,张薇薇,楚世文,王效刚,孙玲,程玉海,王丽君,攸翔,王伟.经皮经冠状动脉室间隔化学消融术治疗梗阻性肥厚型心肌病的近期疗效观察[J].中华心血管病杂志,2001,29(1):8-11. 被引量:40
  • 3LIZQ, CHENGTO, ZHANGWW, et al. Percu- taneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy The Chi- nese experience in 119 patients from a single center [J]. Int J Cardiol, 2004,93:197--202.
  • 4李成洋,石蕴琦,李占全,龙猛.化学消融联合经皮冠状动脉介入术治疗5例肥厚型梗阻性心肌病伴冠心病患者疗效分析[J].临床心血管病杂志,2010,26(2):151-152. 被引量:8
  • 5KNIGHT C J. Five years of percutaneous translumi- hal septal myocardial ablation [J]. Heart, 2000, 83: 255--256.
  • 6VESELKA J, DUCHONOV, R, PALENiCKOVA J, et al. Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hy- pertrophic cardiomyopathy: a single-center prospec- tive, and randomized study [J]. Circ J, 2006, 70.. 1550--1552.
  • 7SATO Y, MATSUMOTO N, KUNIMASA T, et al. Sigmoid-shaped ventricular septum causing mid-ven- tricular obstruction: report of 2 cases [J]. Int J Car- diol, 2009, 132: e97--101.
  • 8OZAKI K, SAKUMA I, MITSUMA K, et al. Effect of cibenzoline and atenolol administration on dynamic left ventricular obstruction due to sigmoid-shaped sep- tum[J]. CircJ, 2008, 72: 2087--2091.
  • 9VESELKA J, TOMASOV P, ZEM? NEK D. Mid- term outcomes of alcohol septal ablation for obstruc- tive hypertrophic cardiomyopathy in patients with sig- moid versus neutral ventricular septum [J]. J Invasive Cardiol, 2012,24:636--640.
  • 10李成洋,李占全,赵颖军,石蕴琦.合并高血压与无高血压的60岁以上肥厚型梗阻性心肌病患者行化学消融临床疗效及安全性比较[J].中国循环杂志,2014,29(3):181-184. 被引量:11

二级参考文献20

  • 1BONNE G, CARRIER L, RICHARD P,et al. Familial hypertrophic cardiomyopathy: from mutations to functional defeets[J].Cire Res, 1998 , 83:580--593.
  • 2SIGWART U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy[J]. Lancet, 1995, 346:211--214.
  • 3LI Z Q, CHENG T O, ZHANG W W,et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy;The Chinese experience in 119 patients from a single center[J]. Int J Cardiol, 2004, 93:197--202.
  • 4KNIGHT C J. Five years of percutaneous transluminal septal myocardial ablation[J]. Heart,2000, 83 : 255-- 256.
  • 5FABER L, MEISSNER A, ZIEMSSEN P,et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients[J]. Heart, 2000 ,83:326--331.
  • 6VESELKA J, DUCHONOVAR, PALENICKOVA J, et al. Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiornyopathy: a single-center prospectire, and randomized study[J]. Cire J, 2006,70:1550 --1552.
  • 7VAN DER LEE C, SCHOLZEL B, TEN BERGJ M, et al. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation[J]. Am J Cardiol, 2008 ,101:1315--1320.
  • 8QIN J X, SHIOTA T, LEVER H M,et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery[J].J Am Coll Cardiol, 2001,38:1994--2000.
  • 9GIETZEN F H, LEUNER C J, RAUTE-KREINSEN U,e al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy[J]. Eur Heart J, 1999,20:1342 --1354.
  • 10Bonne G,Carrier L,Richard P,el al.Familial hypertrophiccardiomyopathy:from mutations to functional defects.Ciro Res,1998,83:580-593.

共引文献54

同被引文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部